Cooley advised the underwriters on Gossamer Bio’s $317.4 million initial public offering of 19,837,500 shares of common stock. Charlie Kim, Sean Clayton, Dave Peinsipp, and Kristin VanderPas led the Cooley team advising the underwriters. This was the 3rd largest life sciences IPO in the 2000s.
Bank of America Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as joint book-running managers for the offering.
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the disease areas of immunology, inflammation and oncology. The company’s shares now trade on the Nasdaq Global Select Market under the symbol “GOSS.”